thalidomide has been researched along with Polycythemia Vera in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is an immunomodulator used to treat 5q-myelodysplastic syndrome, myelofibrosis, and multiple myeloma." | 1.38 | Lenalidomide-induced elevated bilirubin. ( Kolesar, JM; Simondsen, KA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshimoto, G | 1 |
| Miyamoto, T | 1 |
| Dasanu, CA | 1 |
| Schwartz, RA | 1 |
| Bauer, F | 1 |
| Davis, LK | 1 |
| Silver, JS | 1 |
| Reale, MA | 1 |
| Simondsen, KA | 1 |
| Kolesar, JM | 1 |
| Hebballi, S | 1 |
| Akiki, S | 1 |
| Bareford, D | 1 |
1 review available for thalidomide and Polycythemia Vera
| Article | Year |
|---|---|
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, | 2014 |
3 other studies available for thalidomide and Polycythemia Vera
| Article | Year |
|---|---|
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; D | 2011 |
Lenalidomide-induced elevated bilirubin.
Topics: Bilirubin; Humans; Lenalidomide; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Thalid | 2012 |
Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon.
Topics: Bone Marrow Examination; DNA Mutational Analysis; Drug Therapy, Combination; Female; Humans; Immunol | 2012 |